Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-06-25
2009-02-10
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S305000, C546S112000, C546S137000
Reexamination Certificate
active
07488735
ABSTRACT:
New quinuclidine amide derivatives having the chemical structure of general formula (I) and pharmaceutically acceptable salts thereof including quaternary salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions 10 comprising them and their use in therapy as antagonists of M3 muscarinic receptors.
REFERENCES:
patent: 3714357 (1973-01-01), Gueremy et al.
patent: 2155320 (1993-08-01), None
patent: 0 424 021 (1991-04-01), None
patent: 0 747 355 (1996-12-01), None
patent: 0 801 067 (1997-10-01), None
patent: 0 863 141 (1998-09-01), None
patent: 0 930 298 (1999-07-01), None
patent: 2012964 (1970-03-01), None
patent: 9-328469 (1997-12-01), None
patent: WO93/16048 (1993-08-01), None
patent: WO 01/04118 (2001-01-01), None
patent: WO02/00652 (2002-01-01), None
patent: WO 02/051841 (2002-07-01), None
patent: WO 02/053564 (2002-07-01), None
Sternbach et al., Journal of the American Chemical Society (1952), 74, 2219-21.
International Search Report dated Sep. 10, 2003.
Abstract from Patent Abstracts of Japan for 09-328469, published Dec. 22, 1997.
L. Noronha-Blob et al., “Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-carboxylate”,European Journal of Pharmacology, vol. 221, pp. 97-103, 1992.
S.H. Gao et al., “Stereochemistry of the Heterocyclic Alcohols Containing Piperidine Unit”,Chemical Journal of Chinese Universities, vol. 20 No. 2, pp 232-236, 1999.
J. Lars et al., “Some quinuclidine derivatives with potential antimalarial activity”,Acta Pharm. Suecica, vol. 5, pp. 71-76, 1968.
N.N. Godovikov, et al., “Synthesis and muscarinolytic activity of quinuclidinyl benzilate alkyl iodides”, Khim. Farm. Zh., vol. 19, No. 9, pp. 1060-1061, 1985.
H. Konzett and R. Rössler,Arch. Exp. Path. Pharmacol., 195, 71-74 (1940).
F. Leonard and I. Ehrenthal,J. Am. Chem. Soc., vol. 73, 2216-2218 (1951).
E. Atkinson et al.,J. Med. Chem., vol. 20, No. 12, 1612-1617 (1977).
Waelbroeck et al.,Mol. Pharmacol., 38:267-273 (1990).
R. Eglen and S. Hedge,Drug News Perspect., 10(8):462-469 (1997).
Chapter 6, “Cholinergic Transmission,” in H. Rang et al.,Pharmacology, Churchill Livingston, New York (1998).
Chapter 7, “Muscarinic Receptor Agonists and Antagonists,” in Goodman and Gilman'sThe Pharmacological Basis of Therapeutics, 10thedition, McGraw Hill, New York (2001).
Finnegan Henderson Farabow Garrett & Dunner LLP
Laboratorios Almirall S.A.
Rahmani Niloofar
Seaman D. Margaret
LandOfFree
Quinuclidine amide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinuclidine amide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinuclidine amide derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4071633